NextGen NIPS Advanced
Sample Type
Recommended for
Report
NextGen NIPS Advanced also known as Non-invasive Prenatal Screening or Non-invasive Prenatal Testing (NIPT) Advanced is a procedure used to assess the likelihood that a foetus would be born with specific genetic disorders.
NextGen NIPS Advanced is a method used to screen for all 23 pairs of chromosomes (22 pairs of autosomes and one pair of sex chromosomes). Rare autosomal aneuploidies (RAA) are aneuploidies that include monosomy and trisomy of chromosomes other than Trisomy 13, 18, and 21. They frequently lead to unfavourable pregnancy outcomes. Cell-free DNA (cfDNA) can be screened to find RAAs. Clinically significant abnormalities are seen in between 30% and 75% of pregnancies with high risk for RAAs according to NIPT. High-risk results call for confirmation diagnostic tests that use karyotyping or chromosomal microarrays to verify the RAA findings.
RAA can lead to miscarriage, preterm delivery, neurodevelopmental delay, structural abnormalities, fetal growth restriction, and uniparental disomy.
Price : ₹ 19,900
- NextGen NIPS Advanced is intended for use in pregnant women between 10-17 weeks of pregnancy and who are at high risk for the chromosomal aneuploidies.
- NextGen NIPS Advanced is recommended for pregnant women to screen for chromosomal diseases that are brought on by an extra or missing copy of a chromosome (aneuploidy).
- NextGen NIPS Advanced is used to determine the risk for the foetus being born with certain genetic abnormalities such as:
- Down syndrome (trisomy 21, caused by an extra chromosome 21)
- Edwards syndrome (trisomy 18, caused by an extra chromosome 18)
- Patau syndrome (trisomy 13, caused by an extra chromosome 13)
- Extra or missing copies of the X chromosome and Y chromosome, the sex chromosomes)
- Aneuploidies (missing (deleted) or copied (duplicated) sections of a chromosome)
- NextGen NIPS Advanced is recommended for all types of pregnancies.
- NextGen NIPS Advanced is offered to all women after at least 10 weeks of pregnancy.
- NextGen NIPS Advanced is recommended as the first line of screening for all pregnancies, irrespective of the risk.
- NextGen NIPS Advanced is especially significant if the woman is above 30 years of age.
NextGen NIPS Advanced measures foetal cell-free DNA (cfDNA) in the mother’s bloodstream to be able to identify foetal chromosomal or genetic abnormalities including rare autosomal aneuploidies (RAA).
This test requires a blood sample. A tourniquet (elastic) band is placed tightly on the upper arm. The patient is then asked to make a fist. This helps in the build-up of blood filling the veins. The skin is disinfected before needle insertion and the blood sample is collected in vacutainer.
